九安医疗
(002432)
| 流通市值：160.85亿 | | | 总市值：170.74亿 |
| 流通股本：4.47亿 | | | 总股本：4.74亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 506,998,641.12 | 2,592,196,225.39 | 2,092,059,399.68 | 1,350,913,448.99 |
| 营业收入 | 506,998,641.12 | 2,592,196,225.39 | 2,092,059,399.68 | 1,350,913,448.99 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 442,333,724.73 | 1,884,214,150.2 | 1,411,084,823.28 | 906,871,985.57 |
| 营业成本 | 149,770,807.82 | 760,198,389.82 | 592,476,733.3 | 402,299,185.56 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 779,204.23 | 6,582,480.78 | 2,330,786.46 | 1,715,704.34 |
| 销售费用 | 119,621,932.97 | 457,583,724.5 | 312,563,420.61 | 173,396,831.73 |
| 管理费用 | 114,843,204.97 | 405,793,990 | 316,308,436.82 | 204,596,338.29 |
| 研发费用 | 88,219,341.37 | 260,687,058.95 | 177,891,510.59 | 119,029,377.56 |
| 财务费用 | -30,900,766.63 | -6,631,493.85 | 9,513,935.5 | 5,834,548.09 |
| 其中:利息费用 | 18,973,353.68 | 67,161,102.4 | 47,914,041.54 | 30,920,556.61 |
| 其中:利息收入 | 33,343,260.51 | 87,977,360.59 | 54,649,654.1 | 36,059,900.96 |
| 加:公允价值变动收益 | 56,094,362.99 | 739,621,509.38 | 593,446,058.89 | 67,692,159.62 |
| 加:投资收益 | 185,950,284.32 | 712,470,809.9 | 542,894,367.27 | 339,030,457.46 |
| 净敞口套期收益 | - | - | - | 0 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | 47,243.33 | 670,163.79 | 793,408.45 | 752,010.75 |
| 资产减值损失(新) | -534,167.38 | -53,479,088.87 | -8,722,596.15 | -8,913,424.34 |
| 信用减值损失(新) | -3,919,914.6 | -2,629,134.69 | 4,048,548.5 | -3,145,047.29 |
| 其他收益 | 1,252,880.97 | 5,165,782.91 | 4,134,180.58 | 3,299,379.76 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 303,555,606.02 | 2,109,802,117.61 | 1,817,568,543.94 | 842,756,999.38 |
| 加:营业外收入 | 246,505.8 | 1,828,061.58 | 1,637,994.83 | 775,209.35 |
| 减:营业外支出 | 300,643.61 | 4,760,361.13 | 2,074,879.54 | 1,348,454.92 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 303,501,468.21 | 2,106,869,818.06 | 1,817,131,659.23 | 842,183,753.81 |
| 减:所得税费用 | 25,685,810.71 | 306,827,673.26 | 283,555,374.12 | 141,162,898.15 |
| 六、净利润 | 277,815,657.5 | 1,800,042,144.8 | 1,533,576,285.11 | 701,020,855.66 |
| 持续经营净利润 | 277,815,657.5 | 1,800,042,144.8 | 1,533,576,285.11 | 701,020,855.66 |
| 归属于母公司股东的净利润 | 266,282,253.63 | 1,668,727,334.63 | 1,368,641,707.61 | 601,759,508.44 |
| 少数股东损益 | 11,533,403.87 | 131,314,810.17 | 164,934,577.5 | 99,261,347.22 |
| (一)基本每股收益 | 0.6 | 3.81 | 3.19 | 1.38 |
| (二)稀释每股收益 | 0.6 | 3.78 | 3.15 | 1.36 |
| 八、其他综合收益 | 240,079,618.96 | 696,472,446.46 | -141,699,686.58 | 160,567,143.54 |
| 归属于母公司股东的其他综合收益 | 239,038,888.16 | 679,212,858.17 | -130,369,523.89 | 154,084,611.52 |
| 九、综合收益总额 | 517,895,276.46 | 2,496,514,591.26 | 1,391,876,598.53 | 861,587,999.2 |
| 归属于母公司股东的综合收益总额 | 505,321,141.79 | 2,347,940,192.8 | 1,238,272,183.72 | 755,844,119.96 |
| 归属于少数股东的综合收益总额 | 12,574,134.67 | 148,574,398.46 | 153,604,414.81 | 105,743,879.24 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |